Giovanni Caforio (Christopher Goodney/Bloomberg via Getty Images)

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

Five months af­ter MyoKar­dia $MYOK swept its late-stage piv­otal on its lead heart drug — high­light­ing its suc­cess with a pre­ci­sion med ap­proach to car­di­ol­o­gy — Bris­tol My­ers Squibb is step­ping up with a $13.1 bil­lion buy­out tied to a big pre­mi­um.

Bris­tol My­ers is pay­ing $225 a share — a 61% pre­mi­um — to get its hands on the car­dio play­er, high­light­ing its in­ter­est in mava­camten, where ex­ecs see a first-in-class role treat­ing ob­struc­tive hy­per­trophic car­diomy­opa­thy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.